A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

被引：38
作者：
Kobayashi, Takayuki [1 ]
Iwaya, Keiichi [1 ]
Moriya, Tomoyuki [2 ]
Yamasaki, Tamio [2 ]
Tsuda, Hitoshi [3 ]
Yamamoto, Junji [2 ]
Matsubara, Osamu [1 ]
机构：
[1] Natl Def Med Coll, Dept Basic Pathol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan
[2] Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 3598513, Japan
[3] Natl Canc Ctr, Pathol & Clin Lab Div, Chuo Ku, Tokyo 1040045, Japan
来源：
BMC CLINICAL PATHOLOGY | 2013年 / 13卷
关键词：
Ki67 labeling index; p53; IHC panel; Luminal-type breast cancer;
D O I：
10.1186/1472-6890-13-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: Ki67 is widely used in order to distinguish the "A" and "B" subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. Methods: Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index (LI), and uni-and multivariate analyses were performed. Results: Division of the patients based on the immunohistochemistry results into favorable-(low Ki67 LI, p53-negative) and unfavorable-(high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-Meier's curves of both disease-free (P<0.0001) and overall survival (P=0.0007). These differences were much more distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor by multivariate analysis. Conclusion: These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for management of patients with HR-positive breast cancer.
引用
收藏
页数：11
相关论文
共 38 条
[21]  
Viale, G., Giobbie-Hurder, A., Regan, M.M., Coates, A.S., Mastropasqua, M.G., Dell'Orto, P., Maiorano, E., Ohlschlegel, C., Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole (2008) J Clin Oncol, 26 (34), pp. 5569-5575. , 10.1200/JCO.2008.17.0829 18981464
[22]  
Kobayashi, T., Tsuda, H., Moriya, T., Yamasaki, T., Kikuchi, R., Ueda, S., Omata, J., Matsubara, O., Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis (2010) Breast Cancer Res Treat, 123 (3), pp. 733-745. , 10.1007/s10549-009-0672-y 20020198
[23]  
Sakamoto, G., Inaji, H., Akiyama, F., Haga, S., Hiraoka, M., Inai, K., Iwase, T., Sato, T., General rules for clinical and pathological recording of breast cancer 2005 (2005) Breast Cancer, 12 (SUPPL.), pp. 191-S27. , 16410755
[24]  
Millar, E.K., Graham, P.H., McNeil, C.M., Browne, L., O'Toole, S.A., Boulghourjian, A., Kearsley, J.H., Fox, C., Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53 (2011) Br J Cancer, 105 (2), pp. 272-280. , 10.1038/bjc.2011.228 21712826
[25]  
Bago-Horvath, Z., Rudas, M., Dubsky, P., Jakesz, R., Singer, C.F., Kemmerling, R., Greil, R., Jasarevic, Z., Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer (2011) Clin Cancer Res, 17 (24), pp. 7828-7834. , 10.1158/1078-0432.CCR-11-1846 21998336
[26]  
Alba, E., Calvo, L., Albanell, J., De La Haba, J.R., Arcusa Lanza, A., Chacon, J.I., Sanchez-Rovira, P., Bermejo, B., Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study (2012) Ann Oncol, 23 (12), pp. 3069-3074. , 10.1093/annonc/mds132 22674146
[27]  
Domagala, W., Markiewski, M., Harezga, B., Dukowicz, A., Osborn, M., Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein (1996) Clinical Cancer Research, 2 (1), pp. 147-154
[28]  
Pinto, A.E., Andre, S., Laranjeira, C., Soares, J., Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer (2005) Pathology, 37 (1), pp. 45-50. , DOI 10.1080/00313020400011250
[29]  
Wolff, A.C., Hammond, M.E.H., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Hayes, D.F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer (2007) Journal of Clinical Oncology, 25 (1), pp. 118-145. , http://jco.ascopubs.org/cgi/reprint/25/1/118, DOI 10.1200/JCO.2006.09.2775
[30]  
Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.H., Davidson, N.E., Geyer Jr., C.E., Martino, S., Wolmark, N., Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31 (2011) J Clin Oncol, 29 (25), pp. 3366-3373. , 10.1200/JCO.2011.35.0868 21768458
1234